跳至主要内容
临床试验/NCT05015881
NCT05015881Enrolling By Invitation2 期

Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder

University of Pennsylvania1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
Enrolling By Invitation
入组人数
20
试验地点
1
主要终点
FDG uptake (CMRg) in the brain and heart

研究概览

简要总结

The goal of this study is to learn more about how a nutritional supplement "ketone ester" (deltaG ®) has an effect on brain and heart function and on alcohol consumption in individuals with and without alcohol use disorder. The study will use Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scans after a single dose of ketone ester or Placebo in 10 people with alcohol use disorder and 10 healthy control volunteers.

详细描述

The purpose of this research is to study how a nutritional ketone ester may affect brain and heart function in individuals who consume alcohol on a regular basis, and in healthy controls.

The study will see how the brain and heart responds, once after drinking the ketone ester and once without drinking the ester (baseline) using a test called an FDG PET/CT scan. PET/CT scans use small amounts of a radioactive imaging drug, a special camera and a computer to evaluate organ and tissue functions. FDG PET/CT scans are routinely done for evaluation of heart diseases. The study will test how the brain and heart function at rest and while viewing pictures of alcohol.

The study involves 4 or more visits: (1) a consent/screening visit, which can be completed in a single day or divided over multiple days. Portions of the screening may occur using telephone or video conference. (2) In-person MRI (if one hasn't been completed in the past year). (3) In-person study visit that includes the drinking of the ketone ester, a FDG PET/CT scan, and (4) a second in-person visit that a FDG PET/CT scan without drinking the ketone ester. Depending on the scheduling for each of these visits, study involvement will last approximately 8 weeks depending on scheduling restrictions. Following completion of the scan visits (next business day), study staff will follow-up with individuals by phone to ask about any changes to your health and to ensure that they did not experience any side effects from the ketone ester, MRI scan or FDG PET/CT scan.

Screening visit:

  • Informed consent will happen before any study related procedures are performed. Staff will answer all questions during the process. The following will occur at the screening session:
  • Demographic information, such as date of birth, age, biological sex, race, and ethnicity will be collected.
  • Current address and contact information in order to register people into the University of Pennsylvania electronic medical record system.
  • Collection of a urine sample of about 30 mL (approximately 2 tablespoons) to be used for urinalysis, drug screening and pregnancy in women.
  • Breathalyzer test to measure breath alcohol concentration (BrAC). A 0.000% BrAC is required to continue with the visit.
  • Vitals (blood pressure and pulse), weight and height. A doctor or nurse practitioner will do a brief physical exam.
  • Brief psychiatric assessments called the 'CSSRS'. During these interviews, questions will be asked about current and past depressed mood symptoms, as well as other psychiatric symptoms, including suicidal thinking.
  • Complete a brief mental ability test called the 'Shipley Institute of Living Scale'.
  • Short interview regarding alcohol and smoking history, behaviors, and mood and any drug or alcohol use, and questions about any substance cravings or withdrawal symptoms.
  • Psychological questionnaires related to substance use, cravings, risk behaviors, mental health, personality, depression and anxiety, quality of sleep.
  • Complete questions about any current medication, recreational drugs or supplements use.
  • Complete a questionnaire about the presence of metal in the body to determine if it is safe to undergo an MRI.
  • A small amount of blood (approximately 2.75 tablespoons) will be drawn for screening lab tests (a blood count and chemistry panel), genetics and metabolite analysis.
  • Complete an oral swab rapid HIV test. If the test is positive, study staff will draw a tablespoon of blood to conduct a confirmatory HIV blood test (i.e., to confirm the positive oral test). If the blood test are positive for HIV, we will provide a referral for medical care and a copy of the test results.
  • Complete several computer-based tasks on a laptop that will be provided by the study team. These tasks will test the following brain cognition measures including: visual memory, willingness to delay a reward offered, response time in reacting to specific information on the screen, verbal learning and memory, impulsiveness, and reaction time and accuracy when asked to match up a series of test pictures that are different shapes and colors.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria for both study groups (AUD and controls)
  • Age 21 years to 65 years old.
  • Willingness to provide signed, informed consent and commit to completing the procedures in the study
  • Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
  • Participants must agree to not consume alcohol beverages for 24 hours prior to each laboratory session.
  • Inclusion criteria for the AUD group:
  • Meets DSM-5 criteria for current AUD
  • Participants report average weekly ethanol consumption of at least 15 standard drinks weekly over the past month prior to consent (self-report)
  • Minimum 1 year history of heavy drinking (self-report).
  • Must have had last drink within 1 week of PET visits.
  • Alcohol specified as the preferred drug (self-report).
  • Inclusion criteria for the control group:
  • AUDIT score < 6
  • Drinks alcohol 15 standard drinks or less per month and 3 or less standard drinks per occasion.
  • Exclusion both groups:
  • Females who are pregnant or breast-feeding will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test prior to FDG injection.
  • Unwilling or unable to refrain from use, within 24 hours of FDG PET/CT scan procedures, psychoactive medications or medication that may affect study results (e.g., analgesics containing narcotics, antibiotics, anti-inflammatory drugs).
  • Current DSM-5 diagnosis of a major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders that are mild/moderate in both groups; and alcohol in the AUD group) that required hospitalization, or that required daily medications for over 4 weeks in the past year (i.e., antidepressants; anticholinergics; antipsychotics; anxiolytics; lithium; psychotropic drugs not otherwise specified (nos) including herbal products (no drugs with psychomotor effects or with anxiolytics, stimulant, antipsychotic, or sedative properties); sedatives/hypnotics).
  • Positive urine drug screen positive for any substances, other than marijuana, on study visits (may be repeated once and if the result is negative on repeat it is not exclusionary).
  • Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
  • Currently suffering from or with a history of stroke and/or stroke related spasticity per medical record review or self report.
  • History of seizures per medical record review or self report.
  • HIV positive, as the human immunodeficiency virus may affect the brain, per medical record review or self report or by testing at screening.
  • Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI. (self-report, medical record review).
  • Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head, fear of enclosed spaces, or other standard contraindication to MRI (self-report checklist) or PET scanner.
  • Significant claustrophobia or other medical condition preventing subject from lying comfortably flat on his/her back for up to 2 hours in the MRI or PET scanner (self-report).
  • BMI > 35, imaging data acquisition is impaired with high-weight individuals).
  • Vision problems that cannot be corrected with glasses.
  • Judged by the principal investigator or his designee to be an unsuitable candidate for study participation.
  • Exclusion criteria for the control group:
  • Current DSM-5 diagnosis of Alcohol use disorder

排除标准

  • 未提供

研究组 & 干预措施

Ketone ester + echocardiogram + PET FDG scanning visit.

Active Comparator

Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate" (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.

干预措施: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate" (Dietary Supplement)

Ketone ester + echocardiogram + PET FDG scanning visit.

Active Comparator

Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate" (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.

干预措施: FDG (Drug)

Echocardiogram + PET FDG scanning visit.

Other

Subjects will complete a echocardiogram + PET scanning visit. 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.

干预措施: FDG (Drug)

结局指标

主要结局

FDG uptake (CMRg) in the brain and heart

时间窗: 4 hours

The primary outcome measure to be analyzed is a comparisons of AUD subjects and healthy control subjects in the amount of FDG uptake (CMRg metabolic rate of glucose) in brain and heart.

次要结局

  • Amount of FDG uptake (CMRg)(4 hours)
  • Amount of blood glucose (mmol/L or mg/dl)(4 hours)
  • Amount of BHB (beta-hydroxybutyrate) (mmol/L)(4 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验